NO20070721L - Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter - Google Patents

Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter

Info

Publication number
NO20070721L
NO20070721L NO20070721A NO20070721A NO20070721L NO 20070721 L NO20070721 L NO 20070721L NO 20070721 A NO20070721 A NO 20070721A NO 20070721 A NO20070721 A NO 20070721A NO 20070721 L NO20070721 L NO 20070721L
Authority
NO
Norway
Prior art keywords
erbb receptor
predicting
tumor
response
mammal
Prior art date
Application number
NO20070721A
Other languages
English (en)
Norwegian (no)
Inventor
Kevin Hudson
Marie Caroline South
Gayle Marshall
Mehran Sam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20070721L publication Critical patent/NO20070721L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20070721A 2004-07-23 2007-02-08 Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter NO20070721L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59035704P 2004-07-23 2004-07-23
US61902704P 2004-10-18 2004-10-18
PCT/GB2005/002852 WO2006008526A2 (en) 2004-07-23 2005-07-20 Method of predicting the responsiveness oa a tumor to erbb receptor drugs

Publications (1)

Publication Number Publication Date
NO20070721L true NO20070721L (no) 2007-04-20

Family

ID=35107052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070721A NO20070721L (no) 2004-07-23 2007-02-08 Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter

Country Status (11)

Country Link
US (1) US20080286771A1 (es)
EP (1) EP1781815A2 (es)
JP (1) JP2008507264A (es)
AU (1) AU2005263972A1 (es)
BR (1) BRPI0513589A (es)
CA (1) CA2574311A1 (es)
IL (1) IL180333A0 (es)
MX (1) MX2007000944A (es)
NO (1) NO20070721L (es)
TW (1) TW200621998A (es)
WO (1) WO2006008526A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
WO2007101122A2 (en) * 2006-02-24 2007-09-07 University Of Chicago Methods and compositions involving slc17a1
US8486903B2 (en) 2007-10-04 2013-07-16 Agency For Science, Technology And Research (A*Star) TAZ/WWTR1 for diagnosis and treatment of cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en) * 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
CN102202667A (zh) 2008-08-04 2011-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
KR20140044341A (ko) * 2011-06-02 2014-04-14 알막 다이아그노스틱스 리미티드 암에 대한 분자적 진단 검사
KR20150090246A (ko) 2012-12-03 2015-08-05 알막 다이아그노스틱스 리미티드 암을 위한 분자 진단 테스트
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1837025A3 (en) * 2002-06-05 2007-12-19 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
EP1735463A4 (en) * 2004-03-26 2008-10-15 Bristol Myers Squibb Pharma Co BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EPIDERMAL GROWTH FACTOR RECEPTOR IN NON-SMALL CELL LUNG CANCER

Also Published As

Publication number Publication date
US20080286771A1 (en) 2008-11-20
AU2005263972A1 (en) 2006-01-26
EP1781815A2 (en) 2007-05-09
WO2006008526A3 (en) 2006-07-13
BRPI0513589A (pt) 2008-05-13
IL180333A0 (en) 2007-07-04
WO2006008526A2 (en) 2006-01-26
TW200621998A (en) 2006-07-01
MX2007000944A (es) 2007-04-13
CA2574311A1 (en) 2006-01-26
JP2008507264A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
NO20070721L (no) Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter
Cheng et al. Thymic tolerance as a key brake on autoimmunity
Carlberg et al. Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder
Alfano et al. The impact of air pollution on our epigenome: how far is the evidence?(A systematic review)
NZ600235A (en) Methods and compositions for the assessment of drug response
Zhang et al. Possible allelic structure of IgG2a and IgG2c in mice
Maussion et al. Functional DNA methylation in a transcript specific 3′ UTR region of TrkB associates with suicide
Halmai et al. Associations between depression severity and purinergic receptor P2RX7 gene polymorphisms
Setchell et al. The hidden benefits of sex: Evidence for MHC‐associated mate choice in primate societies
Azzato et al. Association between a germline OCA2 polymorphism at chromosome 15q13. 1 and estrogen receptor–negative breast cancer survival
Barde et al. Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide
Gerhold et al. The star-nosed mole reveals clues to the molecular basis of mammalian touch
WO2009117122A3 (en) Genetic analysis
Klengel et al. Gene× environment interactions in the prediction of response to antidepressant treatment
Pishva et al. The epigenome and postnatal environmental influences in psychotic disorders
Vukojevic et al. Evolutionary conserved role of neural cell adhesion molecule-1 in memory
WO2007038670A3 (en) Methods and compositions for screening and treatment of disorders of blood glucose regulation
US10837062B2 (en) Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms
Haenisch et al. Genome-wide association data provide further support for an association between 5-HTTLPR and major depressive disorder
WO2008010195A3 (es) Método y aparato para determinar asociaciones généticas
Logan Do you smell what I smell? Genetic variation in olfactory perception
Moran et al. Genomic resources for darters (Percidae: Etheostominae) provide insight into postzygotic barriers implicated in speciation
EP2730663A3 (en) Genetic factors associated with inhibitor development in hemophilia A
WO2008118415A3 (en) Genetic polymorphisms associated with coronary events and drug response
Carazo-Arias et al. Contribution of the opioid system to the antidepressant effects of fluoxetine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application